StockNews.AI
RXST
StockNews.AI
12 days

RxSight, Inc. Reports Second Quarter 2025 Financial Results

1. RXST's Q2 2025 revenue decreased 4% year-over-year. 2. LAL sales increased by 13%, but LDD sales dropped by 49%. 3. FDA expanded LAL power range, enabling broader market appeal. 4. Company launched LAL system in South Korea and Singapore. 5. Operating expenses rose 20%, impacting net loss significantly.

Earnings
-7.7%Current Return
VS
+0.78%S&P 500
$7.7908/07 04:14 PM EDTEvent Start
$7.1908/08 10:35 PM EDTLatest Updated
17m saved
Insight
Article

FAQ

Why Neutral?

The mixed financial performance shows robust LAL demand but declining LDD sales, showcasing volatility.

How important is it?

The article discusses current performance metrics and future prospects that directly influence RXST's valuation.

Why Short Term?

Immediate fluctuations expected due to current sales trends and operational restructuring.

Related Companies

LDDAAPLAMGN
August 07, 2025 16:05 ET  | Source: RxSight, Inc. ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights Reported second quarter 2025 revenue of $33.6 million, representing a decrease of 4% compared to the second quarter of 2024, reflecting: The sale of 27,380 Light Adjustable Lenses (LAL®/LAL+®), representing a 13% increase in procedure volume compared to the second quarter of 2024;The sale of 40 Light Delivery Devices (LDD™s), representing a 49% decrease compared to the second quarter of 2024; andAn installed base of 1,084 LDDs as of June 30, 2025, representing a 34% increase from 810 LDDs at the end of the second quarter of 2024; During the second quarter, the company received FDA approval to expand the Light Adjustable Lens dioptric power range to -2.0 to +3.0 diopters, along with approvals for new LDD software updates.In the quarter, the company launched the RxSight® Light Adjustable Lens system in South Korea, with a subsequent launch in Singapore in July.Announced a realignment of its commercial organization.Reaffirmed its 2025 full-year revenue, gross margin and operating expense guidance provided on July 8, 2025. “With nearly 1,100 LDD-enabled practices in place, we see significant opportunity to accelerate growth by deepening engagement with our existing customers while strategically expanding our installed base,” said Ron Kurtz, Chief Executive Officer and President of RxSight. “Our newly launched Customer Success Organization, supported by targeted investments in clinical affairs, marketing, and education, is designed to elevate onboarding, strengthen ongoing practice support and advance the mastery of post-operative vision optimization. Together with our realigned commercial structure and selective investments in high-impact areas, these initiatives position us to fully realize the clinical value of the LAL and drive sustained growth.” Second Quarter Financial Results In the second quarter of 2025, total revenue was $33.6 million, representing a decrease of 4% compared to $34.9 million in the second quarter of 2024. During the quarter, LAL revenue increased 13% while LDD revenue decreased 50%, compared to the second quarter of 2024. Gross profit for the second quarter of 2025 was $25.2 million or 74.9% of revenue, an increase of $0.9 million compared to gross profit of $24.3 million or 69.5% of revenue for the second quarter of 2024. The increase in gross profit was primarily driven by the favorable shift in product mix toward LAL sales. Total operating expenses for the second quarter of 2025 were $39.2 million, a 20% increase from $32.6 million in the second quarter of 2024, reflecting the company’s ongoing investments to support increased LAL sales volume, and advance its research and development pipeline.  In the second quarter of 2025, the company reported a net loss of $(11.8) million, or $(0.29) per basic and diluted share, compared to a net loss of $(6.1) million, or $(0.16) per basic and diluted share in the second quarter of 2024. Adjusted net loss in the second quarter of 2025 was $(3.2) million, or $(0.08) per basic and diluted share, compared to an adjusted net gain of $26,000, or $0.00 per basic and diluted share in the second quarter of 2024. Cash, cash equivalents and short-term investments decreased by $1.8 million as of June 30, 2025, to $227.5 million compared to $229.3 million as of March 31, 2025. 2025 Guidance The company reiterated its 2025 full-year revenue, gross margin and operating expense guidance as follows: Revenue of $120.0 million to $130.0 million, representing an implied decrease of 14% to 7% compared to 2024;Gross margin in the range of 72% to 74%, representing an implied increase of 130 basis points to 330 basis points compared to 2024;Operating expenses in the range of $145.0 million to $155.0 million, representing an implied increase of 7% to 14% compared to 2024; andOperating expenses include non-cash stock-based compensation expense in the range of $27.0 million to $30.0 million. Conference Call On Thursday, August 7, 2025, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2025 financial results. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963 and enter the conference code: 9977116. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com. Forward-Looking Statements This press release contains forward-looking statements, including: statements concerning the Company’s projected revenue, gross margin, operating expense and non-cash stock based compensation in 2025; the Company’s potential for accelerated growth by deepening engagement with its existing customers while strategically expanding its installed base; the benefits expected from the Company’s realigned commercial structure and selective investments in high-impact areas; and the Company’s belief that these initiatives will enable it to fully realize the clinical value of the Light Adjustable Lens and drive sustained growth. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended June 30, 2025, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law. Company Contact:Shelley B. ThunenChief Financial Officersthunen@rxsight.com Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@rxsight.com  RxSIGHT, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE LOSS (UNAUDITED)(In thousands, except share and per share amounts)             Three Months Ended June 30,  Six Months Ended June 30,  2025  2024  2025  2024             Sales$33,637  $34,887  $71,531  $64,399 Cost of sales 8,447   10,637   18,013   19,464 Gross profit 25,190   24,250   53,518   44,935 Operating expenses:           Selling, general and administrative 28,976   24,292   57,611   47,616 Research and development 10,217   8,291   20,584   16,322 Total operating expenses 39,193   32,583   78,195   63,938 Loss from operations (14,003)  (8,333)  (24,677)  (19,003)Other income (expense), net:           Interest expense (5)  (6)  (11)  (11)Interest and other income 2,254   2,276   4,762   3,860 Loss before income taxes (11,754)  (6,063)  (19,926)  (15,154)Income tax expense 32   16   50   25             Net loss$(11,786) $(6,079) $(19,976) $(15,179)Other comprehensive loss           Unrealized loss on short-term investments (146)  (64)  (303)  (109)Foreign currency translation gain (loss) 14   (1)  20   (4)Total other comprehensive loss (132)  (65)  (283)  (113)            Comprehensive loss$(11,918) $(6,144) $(20,259) $(15,292)            Net loss per share:           Basic & diluted$(0.29) $(0.16) $(0.49) $(0.40)Weighted-average shares used in computing net loss per share:           Attributable to common stock, basic & diluted 40,743,786   38,455,955   40,627,363   37,649,521                  RxSIGHT, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)(In thousands, except share and per share amounts)  June 30,  December 31,  2025  2024  (Unaudited)    Assets     Current assets:     Cash and cash equivalents$40,355  $16,706 Short-term investments 187,136   220,517 Accounts receivable, net 28,058   30,050 Inventories, net 25,061   22,009 Prepaid and other current assets 3,264   4,541 Total current assets 283,874   293,823 Property and equipment, net 13,255   12,413 Operating leases right-of-use assets 10,588   11,217 Restricted cash 750   750 Other assets 542   360 Total assets$309,009  $318,563 Liabilities and stockholders' equity     Current liabilities:     Accounts payable$3,348  $4,544 Accrued expenses and other current liabilities 15,934   20,358 Lease liabilities 1,101   974 Total current liabilities 20,383   25,876 Long-term lease liabilities 10,614   11,322 Other long-term liabilities —   127 Total liabilities 30,997   37,325 Commitments and contingencies     Stockholders' equity:     Common stock, $0.001 par value, 900,000,000 shares authorized,40,913,380 shares issued and outstanding as of June 30, 2025 and40,428,220 shares issued and outstanding as of December 31, 2024 41   40 Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issuedand outstanding —   — Additional paid-in capital 920,159   903,127 Accumulated other comprehensive (loss) income (117)  166 Accumulated deficit (642,071)  (622,095)Total stockholders' equity 278,012   281,238 Total liabilities and stockholders' equity$309,009  $318,563   Non-GAAP Financial Measures To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss) and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, when calculating adjusted net earnings (loss) and adjusted net earnings (loss) per share, basic and diluted, we exclude stock-based compensation expense because this expense is non-cash in nature and we believe excluding this item provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business. Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for stock-based compensation. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance. Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:  RxSIGHT, INC.GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED)(In thousands, except share and per share amounts)   Three months ended June 30,  For the six months ended June 30,   2025  2024  2025  2024 Common Stock            Numerator:            Net loss available to stockholders, basic and diluted $(11,786) $(6,079) $(19,976) $(15,179)Add:            Stock-based compensation  8,547   6,105   15,687   10,801 Adjusted net earnings (loss) income available to common stockholders, basic and diluted: $(3,239) $26  $(4,289) $(4,378)             Denominator:            Weighted-average shares outstanding, basic  40,743,786   38,455,955   40,627,363   37,649,521 Weighted-average shares outstanding, diluted  40,743,786   44,799,864   40,627,363   37,649,521 Adjusted net earnings (loss) per share, basic $(0.08) $0.00  $(0.11) $(0.12)Adjusted net earnings (loss) per share, diluted $(0.08) $0.00  $(0.11) $(0.12)                 

Related News